Alembic Pharmaceuticals has received US Food & Drug Administration (USFDA) approval for its following Abbreviated New Drug Applications (ANDAs):
1. Final Approval for Deferasirox Tablets 90 mg and 360 mg.
2. Final Approval for Deferasirox Tablets for Oral Suspension, 125 mg, 250 mg, and 500 mg.
3. Tentative Approval for Deferasirox Tablets 180 mg.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
